Peregrine Pharmaceuticals Presents Data Supporting Broad Spectrum Anti-Viral Potential of Tarvacin(TM) at BIO 2005

Peregrine Pharmaceuticals Opens Patient Enrollment for Its Tarvacin(TM) Phase I Solid Cancer Therapy Clinical Trial

Peregrine Pharmaceuticals to Present at Rodman and Renshaw Techvest 2nd Annual Security & Connectivity Investor Conference

Clinical Data Published in Neurosurgery Shows Peregrine Pharmaceuticals' Cotara(R) Holds Promise for Treating Brain Cancer

Peregrine Pharmaceuticals Receives FDA Clearance to Initiate Tarvacin(TM) Anti-Viral Clinical Trial

Data Published in Cancer Research Shows That Tarvacin(TM) Equivalent Plus Docetaxel Inhibits Breast Tumor Growth by 93%

Peregrine Pharmaceuticals Submits Tarvacin(TM) Anti-Viral Investigational New Drug Application

Peregrine Pharmaceuticals' Presentation Time at Investors Conference Changed to 10:50 a.m. EDT on April 28

Peregrine Pharmaceuticals to Present at Wall Street Reporter Investors Conference

Peregrine Pharmaceutical's Tarvacin(TM) Effective in Imaging Prostate Cancer